Effects of DNA topoisomerase II inhibitors on human bone marrow progenitor cells.
Topoisomerase II (topo II) is a target for many cytotoxic agents. Two observations, however, warrant caution in their therapeutic use: first, these agents can inhibit differentiation and second, perturbations in function render the enzyme error-prone. Illegitimate recombination events occurring at sites where topo II acts in differentiation could be particularly important in the development of secondary malignancies (relatively frequent after therapy with agents that target topo II). Topo II inhibitors are heterogeneous in mechanisms of action; in site-specificity of cleavable complex 'entrapment' (where present) and in the relative potency against the two topo II isoforms, all potentially influencing the site of maximum DNA damage. The object of this study was to examine the effect of topo II inhibitors on human haemopoietic precursor cells, to determine which have most impact on differentiation. We selected two which act via cleavable complex entrapment, but with different site preferences (m-AMSA and VP-16), and two acting via other mechanisms (merbarone and fostriecin). VP-16 and m-AMSA showed similar patterns with low dose stimulation of granulocyte-macrophage colony formation and high dose inhibition of all colony types. The stimulation was accompanied by an increase in colony size and blast content, consistent with a low dose inhibition of differentiation. Forstriecin, in contrast, stimulated predominantly mixed and erythroid colonies. Merbarone failed to increase colony formation. Neither produced substantial inhibition of colony formation. The effects on granulocyte-macrophage progenitors were confirmed using 7-day suspension cultures, using nitroblue tetrazolium (NBT) reduction and 3-4,5,dimethylthiazol 2,5-diphenyl tetrazolium bromide (MTT) assays for differentiated cells and total cell mass, respectively. These results demonstrate that the effects of topo II inhibitors on haemopoietic cell proliferation and differentiation are agent-specific and can involve lineage-restricted partial inhibition of differentiation.
Francis
G E
GE
Royal Free Hospital School of Medicine, London, UK.
Tejedor
M C
MC
Berney
J J
JJ
Chresta
C M
CM
Delgado
C
C
Patel
P
P
D000328:Adult; D000475:Alkenes / Q000494:pharmacology; D000677:Amsacrine / Q000494:pharmacology; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology; D001853:Bone Marrow / Q000187:drug effects* / Q000201:enzymology*; D001854:Bone Marrow Cells; D003114:Colony-Forming Units Assay; D004354:Drug Screening Assays, Antitumor; D005047:Etoposide / Q000494:pharmacology; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology*; D006801:Humans; D011090:Polyenes; D011753:Pyrones; D013858:Thiobarbiturates / Q000494:pharmacology; D059005:Topoisomerase II Inhibitors
D000475:Alkenes; D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D011090:Polyenes; D011753:Pyrones; D013858:Thiobarbiturates; D059005:Topoisomerase II Inhibitors; D000677:Amsacrine; D005047:Etoposide; C045459:merbarone; C040313:fostriecin